Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.60 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6435269 | 0.81 | PLAU (0.43) | PLAUATR | |
| SCHEMBL21368004 | 0.80 | TLR8 (0.45) | PLAUPIK3CAPOLBL3MBTL1 | |
| SCHEMBL2220791 | 0.80 | FYN (0.42) | PLAUPOLB | |
| SCHEMBL3146860 | 0.79 | KMT2A (0.46) | PLAUPIK3CAPOLBPDPK1CHEK2 | |
| SCHEMBL18839551 | 0.76 | PLAU (0.49) | PLAUTLR7HTR2CHTR2BATR | |
| SCHEMBL29684472 | 0.74 | HTR2C (0.49) | PLAUHTR2CHTR2BPOLBL3MBTL1 | |
| SCHEMBL15716191 | 0.74 | HTR2C (0.49) | PLAUHTR2CHTR2BPOLBL3MBTL1 | |
| SCHEMBL2656846 | 0.73 | S1PR4 (0.50) | PLAUL3MBTL1S1PR4 | |
| SCHEMBL29223784 | 0.72 | PLAU (0.46) | PLAUTLR7PIK3CAHTR2CHTR2B | |
| SCHEMBL16235172 | 0.72 | GAA (0.42) | PLAUHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050026836-A1 | Composition for the treatment of damaged tissue | DACK KEVIN NEIL (GB) | 2005-02-03 | — | — | US | disclosed |
| EP-1044967-B1 | 2-Pyridinylguanidine urokinase inhibitors | PFIZER (US) | 2004-08-11 | — | — | EP | disclosed |
| US-6673789-B2 | TREATING INFILTRATION OF IMMUNE CELLS INTO INFLAMMATORY SITES | PFIZER, INC. | 2004-01-06 | — | — | US | disclosed |
| US-20030203914-A1 | 2-Pyridinylguanidine urokinase inhibitors | DICKINSON ROGER PETER (GB) | 2003-10-30 | — | — | US | disclosed |
| US-6583162-B1 | 2-pyridinylguanidine urokinase inhibitors | WARNER-LAMBERT COMPANY | 2003-06-24 | — | — | US | disclosed |
| EP-1044967-A2 | 2-Pyridinylguanidine urokinase inhibitors | PFIZER INC. (US) | 2000-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026836-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | PLAU 119/4885TLR7 3684/4885PIK3CA 2954/4885 |
| US-20030203914-A1 | 2-Pyridinylguanidine urokinase inhibitors | PLAU, SERPINE1, REN | PLAU 1/4885TLR7 2257/4885PIK3CA 2968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.